Mix & Match Pfizer, AstraZeneca COVID-19 Vaccine With Moderna Shows Improved Immune Response

A British study evaluating mixing COVID-19 vaccines showed a better immune response in people after the first dose of AstraZeneca Plc AZN or Pfizer Inc PFEBioNTech SE BNTX shots followed by Moderna Inc's MRNA nine weeks later.

  • AstraZeneca-Oxford vaccine followed by a Moderna or Novavax Inc NVAX shot showed higher antibodies and T-cell responses versus two doses of AstraZeneca-Oxford.
  • The study of 1,070 volunteers also found that a dose of the Pfizer-BioNTech vaccine followed by a Moderna shot was better than two doses of the standard Pfizer-BioNTech course.
  • Pfizer-BioNTech followed by Novavax induced higher antibodies than the two-dose Oxford-AstraZeneca schedule, although this schedule induced lower antibody and T-cell responses than the two-dose Pfizer-BioNTech schedule.
  • According to the Oxford University study published in the Lancet medical journal, no safety concerns were raised.
  • Related Link: Johnson & Johnson Booster COVID-19 Shot Shows Encouraging Action After Pfizer/BioNTech Jab.
  • The study supports the flexible use of these vaccines in primary immunization schedules, necessary to help the rapid deployment of these vaccines, especially in low- and middle-income countries.
  • Photo by Johaehn from Pixabay
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechGovernmentNewsHealth CareFDAGeneralBriefsCOVID-19 CoronavirusCOVID-19 Vaccine
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!